Loading…

ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE

DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of antibiotics 1981, Vol.34(8), pp.1026-1032
Main Authors:	ARIOLI, VITTORIO, BERTI, MARISA, CARNITI, GIULIANA, RANDISI, ELEONORA, ROSSI, ELSA, SCOTTI, ROBERTO
Format:	Article
Language:	English
Subjects:	Animals Anti-Bacterial Agents - pharmacology Bacteria - drug effects Bacterial Infections - drug therapy Dose-Response Relationship, Drug Isoniazid - therapeutic use Klebsiella pneumoniae Mice Microbial Sensitivity Tests Mycobacterium tuberculosis Rifampin - analogs & derivatives Rifampin - metabolism Rifampin - pharmacology Rifampin - therapeutic use Streptococcus pneumoniae Streptococcus pyogenes Tuberculosis - drug therapy
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c5836-c532de3fd488c657ff899ce631895b44301d477b41c0d0d3e12ac39cd61e878a3
cites
container_end_page	1032
container_issue	8
container_start_page	1026
container_title	Journal of antibiotics
container_volume	34
creator	ARIOLI, VITTORIO BERTI, MARISA CARNITI, GIULIANA RANDISI, ELEONORA ROSSI, ELSA SCOTTI, ROBERTO
description	DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice in experimental infections caused by Staphylococcus aureus, Streptococcus pyogenes group A, Streptococcus pneumoniae and Klebsiella pneumoniae. In the experimental TB infection in the mouse DL 473 was clearly more active than isoniazide and RAMP, two of the most effective antitubercular drugs in current use. The LD50 in the mouse was significantly higher than that of RAMP and the half-life was about 5 times longer than that of RAMP.
doi_str_mv	10.7164/antibiotics.34.1026
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73854610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15345481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5836-c532de3fd488c657ff899ce631895b44301d477b41c0d0d3e12ac39cd61e878a3</originalsourceid><addsrcrecordid>eNqNkT1v2zAURYmiReKm-QVFAU6dapdPjyKfRlWRGxaKAyRKCk8ETVGpAn-koj3031eGDSNbuzwSuOee5TL2EcREg5Jf3XrbLbrNtvNxgnICIlFv2AiIYAxSZW_ZSIgExkSJOGfvY3wWAjVqOmNnGiHLgEbsRz6rzbe8qMs7k1d8-JhHU8_57ZRfVVxq_MJzPit_8vvyxtzPZ_V1WZuC35lpfjMvzIxfDcXHfGiVH9i71i1juDy-F-xhWtbF9bi6_W6KvBr7lFANF5MmYNtIIq9S3baUZT4oBMrShZQooJFaLyR40YgGAyTOY-YbBYE0Obxgnw_el37zexfi1q666MNy6dZhs4tWI6VSgfgnCCmqVGj6H1CmkmAA8QD6fhNjH1r70ncr1_-xIOx-E_tqE4vS7jcZWp-O-t1iFZpT5zjCkFeH_Dlu3VM45a4fNMvw2gmZor33ePb6E-Z_ud6GNf4FdvGd_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15345481</pqid></control><display><type>article</type><title>ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE</title><source>J-STAGE Free - English</source><creator>ARIOLI, VITTORIO ; BERTI, MARISA ; CARNITI, GIULIANA ; RANDISI, ELEONORA ; ROSSI, ELSA ; SCOTTI, ROBERTO</creator><creatorcontrib>ARIOLI, VITTORIO ; BERTI, MARISA ; CARNITI, GIULIANA ; RANDISI, ELEONORA ; ROSSI, ELSA ; SCOTTI, ROBERTO</creatorcontrib><description>DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice in experimental infections caused by Staphylococcus aureus, Streptococcus pyogenes group A, Streptococcus pneumoniae and Klebsiella pneumoniae. In the experimental TB infection in the mouse DL 473 was clearly more active than isoniazide and RAMP, two of the most effective antitubercular drugs in current use. The LD50 in the mouse was significantly higher than that of RAMP and the half-life was about 5 times longer than that of RAMP.</description><identifier>ISSN: 0021-8820</identifier><identifier>EISSN: 1881-1469</identifier><identifier>DOI: 10.7164/antibiotics.34.1026</identifier><identifier>PMID: 7319918</identifier><language>eng</language><publisher>Japan: JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Bacteria - drug effects ; Bacterial Infections - drug therapy ; Dose-Response Relationship, Drug ; Isoniazid - therapeutic use ; Klebsiella pneumoniae ; Mice ; Microbial Sensitivity Tests ; Mycobacterium tuberculosis ; Rifampin - analogs & derivatives ; Rifampin - metabolism ; Rifampin - pharmacology ; Rifampin - therapeutic use ; Streptococcus pneumoniae ; Streptococcus pyogenes ; Tuberculosis - drug therapy</subject><ispartof>The Journal of Antibiotics, 1981, Vol.34(8), pp.1026-1032</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5836-c532de3fd488c657ff899ce631895b44301d477b41c0d0d3e12ac39cd61e878a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1882,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7319918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ARIOLI, VITTORIO</creatorcontrib><creatorcontrib>BERTI, MARISA</creatorcontrib><creatorcontrib>CARNITI, GIULIANA</creatorcontrib><creatorcontrib>RANDISI, ELEONORA</creatorcontrib><creatorcontrib>ROSSI, ELSA</creatorcontrib><creatorcontrib>SCOTTI, ROBERTO</creatorcontrib><title>ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE</title><title>Journal of antibiotics</title><addtitle>J. Antibiot.</addtitle><description>DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice in experimental infections caused by Staphylococcus aureus, Streptococcus pyogenes group A, Streptococcus pneumoniae and Klebsiella pneumoniae. In the experimental TB infection in the mouse DL 473 was clearly more active than isoniazide and RAMP, two of the most effective antitubercular drugs in current use. The LD50 in the mouse was significantly higher than that of RAMP and the half-life was about 5 times longer than that of RAMP.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacterial Infections - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Isoniazid - therapeutic use</subject><subject>Klebsiella pneumoniae</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><subject>Mycobacterium tuberculosis</subject><subject>Rifampin - analogs & derivatives</subject><subject>Rifampin - metabolism</subject><subject>Rifampin - pharmacology</subject><subject>Rifampin - therapeutic use</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pyogenes</subject><subject>Tuberculosis - drug therapy</subject><issn>0021-8820</issn><issn>1881-1469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><recordid>eNqNkT1v2zAURYmiReKm-QVFAU6dapdPjyKfRlWRGxaKAyRKCk8ETVGpAn-koj3031eGDSNbuzwSuOee5TL2EcREg5Jf3XrbLbrNtvNxgnICIlFv2AiIYAxSZW_ZSIgExkSJOGfvY3wWAjVqOmNnGiHLgEbsRz6rzbe8qMs7k1d8-JhHU8_57ZRfVVxq_MJzPit_8vvyxtzPZ_V1WZuC35lpfjMvzIxfDcXHfGiVH9i71i1juDy-F-xhWtbF9bi6_W6KvBr7lFANF5MmYNtIIq9S3baUZT4oBMrShZQooJFaLyR40YgGAyTOY-YbBYE0Obxgnw_el37zexfi1q666MNy6dZhs4tWI6VSgfgnCCmqVGj6H1CmkmAA8QD6fhNjH1r70ncr1_-xIOx-E_tqE4vS7jcZWp-O-t1iFZpT5zjCkFeH_Dlu3VM45a4fNMvw2gmZor33ePb6E-Z_ud6GNf4FdvGd_w</recordid><startdate>1981</startdate><enddate>1981</enddate><creator>ARIOLI, VITTORIO</creator><creator>BERTI, MARISA</creator><creator>CARNITI, GIULIANA</creator><creator>RANDISI, ELEONORA</creator><creator>ROSSI, ELSA</creator><creator>SCOTTI, ROBERTO</creator><general>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>1981</creationdate><title>ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE</title><author>ARIOLI, VITTORIO ; BERTI, MARISA ; CARNITI, GIULIANA ; RANDISI, ELEONORA ; ROSSI, ELSA ; SCOTTI, ROBERTO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5836-c532de3fd488c657ff899ce631895b44301d477b41c0d0d3e12ac39cd61e878a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacterial Infections - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Isoniazid - therapeutic use</topic><topic>Klebsiella pneumoniae</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><topic>Mycobacterium tuberculosis</topic><topic>Rifampin - analogs & derivatives</topic><topic>Rifampin - metabolism</topic><topic>Rifampin - pharmacology</topic><topic>Rifampin - therapeutic use</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pyogenes</topic><topic>Tuberculosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ARIOLI, VITTORIO</creatorcontrib><creatorcontrib>BERTI, MARISA</creatorcontrib><creatorcontrib>CARNITI, GIULIANA</creatorcontrib><creatorcontrib>RANDISI, ELEONORA</creatorcontrib><creatorcontrib>ROSSI, ELSA</creatorcontrib><creatorcontrib>SCOTTI, ROBERTO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ARIOLI, VITTORIO</au><au>BERTI, MARISA</au><au>CARNITI, GIULIANA</au><au>RANDISI, ELEONORA</au><au>ROSSI, ELSA</au><au>SCOTTI, ROBERTO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE</atitle><jtitle>Journal of antibiotics</jtitle><addtitle>J. Antibiot.</addtitle><date>1981</date><risdate>1981</risdate><volume>34</volume><issue>8</issue><spage>1026</spage><epage>1032</epage><pages>1026-1032</pages><issn>0021-8820</issn><eissn>1881-1469</eissn><abstract>DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice in experimental infections caused by Staphylococcus aureus, Streptococcus pyogenes group A, Streptococcus pneumoniae and Klebsiella pneumoniae. In the experimental TB infection in the mouse DL 473 was clearly more active than isoniazide and RAMP, two of the most effective antitubercular drugs in current use. The LD50 in the mouse was significantly higher than that of RAMP and the half-life was about 5 times longer than that of RAMP.</abstract><cop>Japan</cop><pub>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</pub><pmid>7319918</pmid><doi>10.7164/antibiotics.34.1026</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0021-8820
ispartof	The Journal of Antibiotics, 1981, Vol.34(8), pp.1026-1032
issn	0021-8820 1881-1469
language	eng
recordid	cdi_proquest_miscellaneous_73854610
source	J-STAGE Free - English
subjects	Animals Anti-Bacterial Agents - pharmacology Bacteria - drug effects Bacterial Infections - drug therapy Dose-Response Relationship, Drug Isoniazid - therapeutic use Klebsiella pneumoniae Mice Microbial Sensitivity Tests Mycobacterium tuberculosis Rifampin - analogs & derivatives Rifampin - metabolism Rifampin - pharmacology Rifampin - therapeutic use Streptococcus pneumoniae Streptococcus pyogenes Tuberculosis - drug therapy
title	ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A48%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANTIBACTERIAL%20ACTIVITY%20OF%20DL%20473,%20A%20NEW%20SEMISYNTHETIC%20RIFAMYCIN%20DERIVATIVE&rft.jtitle=Journal%20of%20antibiotics&rft.au=ARIOLI,%20VITTORIO&rft.date=1981&rft.volume=34&rft.issue=8&rft.spage=1026&rft.epage=1032&rft.pages=1026-1032&rft.issn=0021-8820&rft.eissn=1881-1469&rft_id=info:doi/10.7164/antibiotics.34.1026&rft_dat=%3Cproquest_cross%3E15345481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5836-c532de3fd488c657ff899ce631895b44301d477b41c0d0d3e12ac39cd61e878a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15345481&rft_id=info:pmid/7319918&rfr_iscdi=true